Unicycive Therapeutics
UNCY
29 hedge funds and large institutions have $34.5M invested in Unicycive Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
1.71% less ownership
Funds ownership: 59.44% → 57.73% (-1.7%)
3% less funds holding
Funds holding: 30 → 29 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
30% less capital invested
Capital invested by funds: $49M → $34.5M (-$14.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$854K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.4K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$30.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$30.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$1.17M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$610K |
| 3 |
Walleye Capital
New York
|
-$552K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$44.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$29.4K |
UNCY Hedge Fund Activity: Q1 2025 in Review
29 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2025, worth a combined $34.5M — down 30% from $49M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of UNCY and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 9 added.
The largest buyer was Vivo Capital, adding an estimated $854K. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.17M sold.
- 29 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2025, down from 30 in Q4 2024.
- Funds reported $34.5M of Unicycive Therapeutics stock for Q1 2025, down 30% quarter-over-quarter.
- 5 funds opened new Unicycive Therapeutics positions in Q1 2025 and 6 closed out, a net change of -1 holder.
- The largest Unicycive Therapeutics buyer in Q1 2025 was Vivo Capital, an estimated $854K added.
- The largest Unicycive Therapeutics seller in Q1 2025 was Altium Capital Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2025.